Mayar Capital Ltd. Has $6.62 Million Holdings in Solventum Corporation (NYSE:SOLV)

Mayar Capital Ltd. raised its stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 187.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,990 shares of the company's stock after buying an additional 56,700 shares during the period. Solventum accounts for approximately 11.7% of Mayar Capital Ltd.'s portfolio, making the stock its 3rd biggest holding. Mayar Capital Ltd. owned 0.05% of Solventum worth $6,615,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of SOLV. Norges Bank acquired a new stake in Solventum during the fourth quarter worth about $203,740,000. Boston Partners acquired a new stake in Solventum during the fourth quarter valued at approximately $110,378,000. Trian Fund Management L.P. boosted its holdings in shares of Solventum by 18.8% in the 4th quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock worth $559,054,000 after acquiring an additional 1,336,564 shares in the last quarter. Independent Franchise Partners LLP boosted its holdings in shares of Solventum by 105.0% in the 4th quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company's stock worth $105,904,000 after acquiring an additional 821,272 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Solventum by 738.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 566,623 shares of the company's stock worth $43,086,000 after acquiring an additional 499,031 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SOLV. KeyCorp began coverage on Solventum in a report on Friday, June 6th. They issued a "sector weight" rating on the stock. Piper Sandler raised Solventum from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $78.00 to $87.00 in a report on Monday, May 19th. Argus raised Solventum from a "hold" rating to a "buy" rating and set a $90.00 target price on the stock in a report on Tuesday, July 1st. Finally, Morgan Stanley upgraded shares of Solventum from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $80.00 to $103.00 in a research report on Tuesday. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $84.38.

Solventum Trading Down 0.8%

Shares of Solventum stock traded down $0.58 on Friday, hitting $73.29. 301,168 shares of the company's stock traded hands, compared to its average volume of 1,092,643. The firm's 50-day moving average price is $74.13 and its two-hundred day moving average price is $72.62. The stock has a market capitalization of $12.68 billion, a PE ratio of 33.93, a price-to-earnings-growth ratio of 1.87 and a beta of 0.55. Solventum Corporation has a one year low of $52.40 and a one year high of $85.92. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.19 and a quick ratio of 0.85.

Solventum (NYSE:SOLV - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.19 by $0.15. The company had revenue of $2.07 billion during the quarter, compared to analysts' expectations of $2.02 billion. Solventum had a net margin of 4.55% and a return on equity of 31.01%. The business's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.08 EPS. On average, research analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.